ArticleClinical, cosmetic and investigational dermatology2026
Integrative Multi-Omics and Experimental Analyses Identify TAPBP as a Key Mediator Linking Genetic Susceptibility to Melanocyte Dysfunction in Vitiligo.
Article in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Vitiligo is an autoimmune depigmenting disorder characterized by selective melanocyte loss; however, the specific molecular bridges between genetic risk variants and melanocyte-intrinsic immune vulnerability remain largely unexplored. Objective: To elucidate the molecular link between genetic susceptibility and melanocyte injury in vitiligo by integrating multi-omics data. Methods: We integrated large-scale genome-wide association data (FinnGen R12, n=466,064), expression quantitative trait loci (eQTLgen, n=31,684), and single-cell transcriptomic profiles to identify genes mediating vitiligo susceptibility. Results: Cross-omic analysis identified TAPBP as a top candidate, which is significantly upregulated in lesional melanocytes and core to the antigen-processing network. Functional validation in human melanocytes demonstrated that TAPBP overexpression significantly increased HLA class I expression, suppressed cell proliferation, and induced apoptosis. Transcription factor analysis further identified STAT2 as a key upstream regulator, linking interferon signaling to aberrant antigen presentation. Conclusion: These findings suggest that the STAT2-TAPBP axis enhances melanocyte immunogenicity and vulnerability to cytotoxic attack. Our study provides a novel mechanistic link between genetic variation and immune-mediated destruction, positioning TAPBP as a potential biomarker and a target for precision immunotherapy in vitiligo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.